Side effects of COVID-19 vaccines in paediatric patients: a review systematic and meta-analysis protocol.

Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101552874 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-6055 (Electronic) Linking ISSN: 20446055 NLM ISO Abbreviation: BMJ Open

Original Publication: [London] : BMJ Publishing Group Ltd, 2011-

Systematic Reviews as Topic* ; COVID-19 Vaccines*/adverse effects ; COVID-19 Vaccines*/administration & dosage ; COVID-19*/prevention & control ; Meta-Analysis as Topic* ; SARS-CoV-2*/immunology; Humans ; Child ; Research Design

Introduction: The paediatric population represents a quarter of the world's population, and like adult patients, they have also suffered immeasurably from the SARS-CoV-2 pandemic. Immunisation is an effective strategy for reducing the number of COVID-19 cases. With the advancements in vaccination for younger age groups, parents or guardians have raised doubts and questions about adverse effects and the number of doses required. Therefore, systematic reviews focusing on this population are needed to consolidate evidence that can help in decision-making and clinical practice. This protocol aims to assess the safety of COVID-19 vaccines in paediatric patients and evaluate the correlation between the number of vaccine doses and side effects.
Methods and Analysis: We will search the PubMed, ClinicalTrials.gov, Web of Science, Embase, CINAHL, Latin American and Caribbean Health Sciences Literature, Scopus and Cochrane databases for randomised and quasi-randomised clinical trials that list the adverse effects of the COVID-19 vaccine and assess its correlation with the number of doses, without any language restrictions. Two reviewers will select the studies according to the inclusion and exclusion criteria, extract data and asses for risk of bias using the Cochrane risk-of-bias tool. The Review Software Manager (RevMan V.5.4.1) will be used to synthesise the data. We will use the Working Group's Grading of Recommendations Assessment, Development and Evaluations to grade the strength of the evidence of the results.
Ethics and Dissemination: Formal ethical approval is not required as no primary data are collected. This systematic review will be disseminated through a peer-reviewed publication.
Prospero Registration Number: CRD42023390077.
Competing Interests: Competing interests: None declared.
(© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)

JAMA. 2020 Jul 21;324(3):259-269. (PMID: 32511692)
Lancet. 2020 May 23;395(10237):1607-1608. (PMID: 32386565)
Vaccines (Basel). 2021 Sep 29;9(10):. (PMID: 34696210)
Pediatr Clin North Am. 2021 Oct;68(5):961-976. (PMID: 34538306)
Lancet. 2020 Jun 6;395(10239):1771-1778. (PMID: 32410760)
Lancet. 2021 Apr 10;397(10282):1351-1362. (PMID: 33798499)
Pediatr Infect Dis J. 2020 Nov;39(11):e340-e346. (PMID: 32925547)
Rev Med Suisse. 2021 Feb 17;17(726):353-357. (PMID: 33599412)
BMJ. 2015 Jan 02;350:g7647. (PMID: 25555855)
Cureus. 2019 Jul 2;11(7):e5067. (PMID: 31516778)
Vaccines (Basel). 2021 Apr 01;9(4):. (PMID: 33916277)
J Infect. 2022 May;84(5):722-746. (PMID: 35108601)
Nat Rev Immunol. 2021 Aug;21(8):475-484. (PMID: 34211186)
Arch Dis Child. 2022 Mar;107(3):e1. (PMID: 34732388)
Vaccines (Basel). 2021 May 06;9(5):. (PMID: 34066475)
Lancet Infect Dis. 2021 Oct;21(10):1383-1394. (PMID: 33887208)
Signal Transduct Target Ther. 2020 Oct 13;5(1):237. (PMID: 33051445)
J Clin Epidemiol. 2011 Apr;64(4):383-94. (PMID: 21195583)
N Engl J Med. 2020 Dec 17;383(25):2439-2450. (PMID: 33053279)

Keywords: Adolescent; COVID-19; Child protection; IMMUNOLOGY

0 (COVID-19 Vaccines)

Date Created: 20240409 Date Completed: 20240807 Latest Revision: 20240807

20240808

PMC11015277

10.1136/bmjopen-2023-076064

38594182